Evidence map›Paper›PMID 39264523›Full record

ArticleInvestigational new drugs2024

Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia.

Liping Peng, Zhaoquan Wu, Wei Sun, Chunjiang Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Role of regulatory immune cells in pathogenesis and therapy of periodontitis.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liping PengDepartment of Cardiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Zhaoquan WuCollege of pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
Wei SunDepartment of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Chunjiang WangCollege of pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China. wongcj@csu.edu.cn.

Funding

Natural Science Foundation of Hunan Province 2022JJ30874
6 · The paper itself

Abstract

Immune thrombocytopenia (ITP) represents an uncommon hematological side effect associated with nivolumab, and its distinct clinical attributes remain poorly defined. This research aimed to explore the clinical manifestations and outcomes of ITP induced by nivolumab. Reports on nivolumab induced ITP up to April 30, 2024, were collected for retrospective analysis. The study involved 34 patients with a median age of 67 years (range 32, 82). The onset of ITP varied from 10 to 100 days post initial dosage, with a median onset at 70 days. The majority of patients exhibited no symptoms, with only 23.5% experiencing clinically significant bleeding and 11.8% facing non-clinically significant bleeding. The median platelet count was 12 × 10

Indexed as

NivolumabPurpura, Thrombocytopenic, IdiopathicAdultAgedAged, 80 and overAntineoplastic Agents, ImmunologicalFemaleHumansMaleMiddle AgedPlatelet CountRetrospective StudiesTreatment OutcomeAntineoplastic Agents, ImmunologicalNivolumabImmune checkpoint inhibitorImmune-related adverse eventImmune thrombocytopeniaNivolumabPharmacovigilance

Identifiers

PMID39264523

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.